scholarly journals Bioactive Components and Health Benefits of Saskatoon Berry

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Lunan Zhao ◽  
Fei Huang ◽  
Amy Leung Hui ◽  
Garry X. Shen

In response to the recent rise in numbers of diabetes patients, many treatments have been developed; but currently, oral antihyperglycemic agents and insulin are still the main clinical treatments. Since current drugs have limitations and harmful side effects, research in alternative treatments has been sought. This article reviews recent research updates of Saskatoon berries (SB), covering its background information, its main active ingredients, its structure, and its function. Flavonoid compounds in Saskatoon berries, in particular flavanol, anthocyanin, and proanthocyanin, possess anti-inflammatory, antitumor, and antidiabetes impacts. The current review synthesizes the latest research on the health benefits of Saskatoon berry in a variety of domains. With further research, SB has the potential to help treat and prevent diabetes in the future.

Author(s):  
Vikash Kumar ◽  
Sandeep Rathor

: All groups/patient's quality of life (QOL) affects because of overactive bladder (OAB) which leads to symptoms like urgency/urinary frequency/incontinence and nocturia. Several patients do not undergo management because of the embarrassment/misconception i.e. it’s related to aging only and even discontinue the treatment due to side effects (repeated incidences). The objective of this review to explore all management methods (including active ingredients involved in the treatment) and envisage the future scope of the different nano methods with minimizing apparent side effects to achieve a significant effect.


2018 ◽  
Vol 2 (1) ◽  
pp. 17-21
Author(s):  
Surahmaida .

ABSTRAKDi dunia, jamur Ganodermatelah dikenal sebagai jamur obat. Ganoderma lebih dikenal dengan sebutan jamur Lingzhi atau Reishi. Dari 2000 spesies Ganoderma, hanya 6 spesies yang telah diteliti memiliki efek potensial dalam bidang kesehatan, yaitu G. lucidum, G. applanatum, G. tsugae, G. oregonense, G. boninense, dan G. neojapanicum. Kandungan senyawa bioaktif yang terkandung di dalam Ganoderma terus dikembangkan dalam pemanfaatannya sebagai obat alternatif. Hal inilah yang menyebabkan jamur Ganoderma bebas dari efek samping.Enam spesies Ganoderma ini memiliki karakteristik dengan berbagai potensi kesehatan yang berbedabeda dan berkhasiat sebagai bahan obat. Dari keenam Ganoderma, hanya G. boninense yang memiliki toksisitas terhadap larva udang Artemia salina.Kata Kunci: Tipe-tipe Ganoderma sp, karakteristik fisik, senyawa bioaktif, manfaat Ganoderma sp. bagi kesehatanABSTRACTIn the world, the fungus Ganoderma has been known as a medicinal mushroom. Ganoderma is known as Lingzhi or Reishi mushroom. From 2000 Ganoderma species, only six species that have been studied have a potential effect on health, namely G. lucidum, G. applanatum, G. tsugae, G. oregonense, G. boninense, and G. neojapanicum. The content of bioactive compounds contained in Ganoderma continue to be developed in their usage as an alternative medicine. This is what causes the fungus Ganoderma is free from side effects. Six speciesof Ganoderma has characteristics with various health potentials that vary and efficacious as a drug ingredient. Of the six Ganoderma, only G. boninense has toxicity to the shrimp larvae of Artemia salina.Keywords: Types of Ganodermasp., physical characteristics, bioactive components, health benefits of Ganoderma sp.


2020 ◽  
Vol 13 ◽  
Author(s):  
Sajad Fakhri ◽  
Jayanta Kumar Patra ◽  
Swagat Kumar Das ◽  
Gitishree Das ◽  
Mohammad Bagher Majnooni ◽  
...  

Background: As a major cause of morbidity and mortality, cardiovascular diseases (CVDs) are globally increasing. In spite of recent development in the management of cardiovascular complications, CVDs have remained a medical challenge. Numerous conventional drugs are used to play cardioprotective roles; however, they are associated with several side effects. Considering the rich phytochemistry and fewer side effects of herbal medicines, they have gained particular attention to develop novel herbal drugs with cardioprotective potentials. Amongst natural entities, ginger is an extensively used and well-known functional food and condiment, possessing plentiful bioactivities, like antiinflammatory, antioxidant, and antimicrobial properties in several disorders management. Objective: The current review deliberated phytochemical properties as well as the ginger/ginger constituents' biological activities and health benefits in several diseases, with particular attention to cardiovascular complications. Methods: A comprehensive research was conducted using multiple databases, including Scopus, PubMed, Medline, Web of Science, national database (Irandoc and SID), and related articles in terms of the health benefits and cardioprotective effects of ginger/ginger constituents. These data were collected from inception until August 2019. Results: In recent years, several herbal medicines were used to develop new drugs with more potency and also minor side effects. Amongst natural entities, ginger is an extensively used traditional medicine in several diseases. The crude extract, along with related pungent active constituents, is mostly attributed to heart health. The cardioprotective effects of ginger are contributed to its cardiotonic, antihypertensive, anti-hyperlipidemia, and anti-platelet effects. The signaling pathways and molecular mechanisms of ginger regarding its cardioprotective effects are also clarified. Conclusion: This study revealed the biological activities, health benefits, and cardioprotective properties of ginger/ginger constituents along with related mechanisms of action, which gave new insights to show new avenue in the treatment of CVDs.


2021 ◽  
Vol 11 (2) ◽  
pp. 127 ◽  
Author(s):  
Beste Turanli ◽  
Esra Yildirim ◽  
Gizem Gulfidan ◽  
Kazim Yalcin Arga ◽  
Raghu Sinha

Pancreatic cancer is one of the most fatal malignancies and the seventh leading cause of cancer-related deaths related to late diagnosis, poor survival rates, and high incidence of metastasis. Unfortunately, pancreatic cancer is predicted to become the third leading cause of cancer deaths in the future. Therefore, diagnosis at the early stages of pancreatic cancer for initial diagnosis or postoperative recurrence is a great challenge, as well as predicting prognosis precisely in the context of biomarker discovery. From the personalized medicine perspective, the lack of molecular biomarkers for patient selection confines tailored therapy options, including selecting drugs and their doses or even diet. Currently, there is no standardized pancreatic cancer screening strategy using molecular biomarkers, but CA19-9 is the most well known marker for the detection of pancreatic cancer. In contrast, recent innovations in high-throughput techniques have enabled the discovery of specific biomarkers of cancers using genomics, transcriptomics, proteomics, metabolomics, glycomics, and metagenomics. Panels combining CA19-9 with other novel biomarkers from different “omics” levels might represent an ideal strategy for the early detection of pancreatic cancer. The systems biology approach may shed a light on biomarker identification of pancreatic cancer by integrating multi-omics approaches. In this review, we provide background information on the current state of pancreatic cancer biomarkers from multi-omics stages. Furthermore, we conclude this review on how multi-omics data may reveal new biomarkers to be used for personalized medicine in the future.


Data ◽  
2021 ◽  
Vol 6 (1) ◽  
pp. 3
Author(s):  
Irene López-Rodríguez ◽  
César F. Reyes-Manzano ◽  
Israel Reyes-Ramírez ◽  
Tania J. Contreras-Uribe ◽  
Lev Guzmán-Vargas

Quantitative and qualitative data on active-ingredient drug composition are essential information for characterizing near-field exposure of consumers to product-related chemicals, among other things. Equally as important is the characterization of the relationship between one or many active ingredients in terms of the diseases they are prescribed for. Such evaluations, however, require quantitative information at different anatomical levels. To complement the available sources of information on active substances and diseases, we have designed a database with enough versatility to potentially be used in a variety of analyzes. By using information provided by a well-established online pharmacological dictionary, we present a database with 11 tables which are easy to access and manipulate. Specifically, we present datasets containing the details of 12,827 marketed drug products, 40,164 diseases, 6231 active pharmaceutical ingredients and 4093 side effects. We exemplify the usefulness of our database with three simple visualizations, which confirm the importance of the data for quantifying the complexity in the associations among active substances, diseases and side effects. Although there are databases with detailed information on active substances and diseases, none of them can be found in Spanish. Our work presents an option that contributes substantially to obtaining well classified information in order to evaluate the roles of active pharmaceutical ingredients, diseases and side effects. These datasets also provide information about clinical and pharmacological groupings which may be useful for clinical and academic researchers. The database will be regularly updated and extended with the newly available Virtual Medicinal Products.


Cells ◽  
2021 ◽  
Vol 10 (10) ◽  
pp. 2529
Author(s):  
Lee-Maine L. Spies ◽  
Nicolette J. D. Verhoog ◽  
Ann Louw

For over 70 years, the unique anti-inflammatory properties of glucocorticoids (GCs), which mediate their effects via the ligand-activated transcription factor, the glucocorticoid receptor alpha (GRα), have allowed for the use of these steroid hormones in the treatment of various autoimmune and inflammatory-linked diseases. However, aside from the onset of severe side-effects, chronic GC therapy often leads to the ligand-mediated downregulation of the GRα which, in turn, leads to a decrease in GC sensitivity, and effectively, the development of acquired GC resistance. Although the ligand-mediated downregulation of GRα is well documented, the precise factors which influence this process are not well understood and, thus, the development of an acquired GC resistance presents an ever-increasing challenge to the pharmaceutical industry. Recently, however, studies have correlated the dimerization status of the GRα with its ligand-mediated downregulation. Therefore, the current review will be discussing the major role-players in the homologous downregulation of the GRα pool, with a specific focus on previously reported GC-mediated reductions in GRα mRNA and protein levels, the molecular mechanisms through which the GRα functional pool is maintained and the possible impact of receptor conformation on GC-mediated GRα downregulation.


2019 ◽  
Author(s):  
Shahanas E ◽  
Seeja T Panjikkaran ◽  
Sharon C L ◽  
Remya P R

Cocoa is regarded as a super food due to its high nutrient content and proven health benefits. Cocoa beans are rich in carbohydrate (31%), protein (11%), fat (54%), fibre (16%) and minerals. Cocoa is a good source of bioactive compounds too. The major bioactive components are polyphenols constituted of flavanoids and non flavanoids. The bioactive components with rich antioxidants and anti-inflammatory activities contribute to various health benefits. The flavonoid rich chocolates improve peripheral vascular function. The consumption of cocoa or chocolate are beneficial in inhibiting the complex molecular process leading to cancer. Flavanoids in cocoa increases insulin sensitivity by improving endothelial function and reducing oxidative stress. The cocoa flavonoids also penetrate and accumulate in the brain regions involved in learning and memory. The knowledge on bioactive compounds in cocoa and cocoa products suggests that they could be consumed as a part of wholesome, health promoting nutritional food.


2019 ◽  
Vol 8 (4) ◽  
pp. 2289-2298

The purpose in this paper is to identify the cost components which are vital in consideration towards manufacturing especially in pharmaceutical companies. The manufacturing costs are significant in total expenses in pharmaceutical industry. In this study, a thorough investigation on the cost components and the trend in expenses and operating profit of pharma companies are studied, giving due regard to cost components to have understanding and to find out how they may differ among various types of pharma companies. The data published in the annual reports from 2009 to 2018 of top five pharmaceutical companies based on their annual revenues has been selected for further diagnosis. The analysis reveals that manufacturing costs are different for all the five companies. The study also reveals that there is a considerable indication that the companies are conscious on the much-needed health benefits to the society in the future at an affordable cost


Sign in / Sign up

Export Citation Format

Share Document